更新于：2024-09-21
Memantine hydrochloride
盐酸美金刚
更新于：2024-09-21
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 德国 (2000-08-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C12H22ClN |
InChIKeyLDDHMLJTFXJGPI-UHFFFAOYSA-N |
CAS号41100-52-1 |
关联
342
项与 盐酸美金刚 相关的临床试验Therapeutic Drug Monitoring (TDM) with different tolerable doses of memantine for cognitive function preservation in Indian patients with brain metastasis treated with radiation. - NIL
A Phase II Clinical Trial of of Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy
To study Memantine as an add-on drug to Escitalopram for Geriatric depression: A double-blind trial - NIL
100 项与 盐酸美金刚 相关的临床结果
登录后查看更多信息
100 项与 盐酸美金刚 相关的转化医学
登录后查看更多信息
100 项与 盐酸美金刚 相关的专利（医药）
登录后查看更多信息
204
项与 盐酸美金刚 相关的文献（医药）2024-08-01BIOMEDICINE & PHARMACOTHERAPY
Mitigating radiation-induced brain injury via NLRP3/NLRC4/Caspase-1 pyroptosis pathway: Efficacy of memantine and hydrogen-rich water
Article
作者: Luo, Hao ; Liu, Huan ; Xu, Kai ; Wang, Yuhao ; Liu, Mengya ; Lu, Xiaoyu ; Wang, Yong ; Qin, Xiujun ; Sun, Ge
Radiation-induced brain injury (RIBI) is a significant challenge in radiotherapy for head and neck tumors, impacting patients' quality of life. In exploring potential treatments, this study focuses on memantine hydrochloride and hydrogen-rich water, hypothesized to mitigate RIBI through inhibiting the NLRP3/NLRC4/Caspase-1 pathway. In a controlled study involving 40 Sprague-Dawley rats, divided into five groups including a control and various treatment groups, we assessed the effects of these treatments on RIBI. Post-irradiation, all irradiated groups displayed symptoms like weight loss and salivation, with notable variations among different treatment approaches. Particularly, hydrogen-rich water showed a promising reduction in these symptoms. Histopathological analysis indicated substantial hippocampal damage in the radiation-only group, while the groups receiving memantine and/or hydrogen-rich water exhibited significant mitigation of such damage. Molecular studies, revealed a decrease in oxidative stress markers and an attenuated inflammatory response in the treatment groups. Immunohistochemistry further confirmed these molecular changes, suggesting the effectiveness of these agents. Echoing recent scientific inquiries into the protective roles of specific compounds against radiation-induced damages, our study adds to the growing body of evidence on the potential of memantine and hydrogen-rich water as novel therapeutic strategies for RIBI.
2024-04-09Pharmaceutical nanotechnology
Optimizing Neuroprotective Nano-structured Lipid Carriers for
Transdermal Delivery through Artificial Neural Network
Article
作者: Prajapati, Bhupendra ; Dalwadi, Saloni ; Thakkar, Vaishali
Background:::
Dementia associated with Alzheimer’s disease (AD) is a neurological disorder.
AD is a progressive neurodegenerative condition that predominantly impacts the elderly population,
although it can also manifest in younger people through the impairment of cognitive functions,
such as memory, cognition, and behaviour. Donepezil HCl and Memantine HCl are encapsulated
in Nanostructured Lipid Carriers (NLCs) to prolong systemic circulation and minimize the systemic
side effects.
Objective:::
This work explores the use of data mining tools to optimize the formulation of NLCs
comprising of Donepezil HCl and Memantine HCl for transdermal drug delivery. Neuroprotective
drugs and excipients are utilized for protecting the nervous system against damage or degeneration.
Method:::
The NLCs were formulated using a high-speed homogenization technique followed by ultrasonication.
NLCs were optimized using Box Behnken Design (BBD) in Design Expert Software
and artificial neural network (ANN) in IBM SPSS statistics. The independent variables included the
ratio of solid lipid to liquid lipid, the percentage of surfactant, and the revolutions per minute (RPM)
of the high-speed homogenizer.
Results:::
The NLCs that were formulated had a mean particle size ranging from 67.0±0.45 to
142.4±0.52nm. Both drugs have a %EE range over 75%, and Zeta potential was determined to be -
26±0.36mV. CryoSEM was used to do the structural study. The permeation study showed the prolonged
release of the formulation.
Conclusion:::
The results indicate that NLCs have the potential to be a carrier for transporting medications
to deeper layers of the skin and reaching systemic circulation, making them a suitable formulation
for the management of Dementia. Both ANN and BBD techniques are effective tools for systematically
developing and optimizing NLC formulation.
2024-02-01Analytical science advances
Screening stabilisers for cyanoenone triterpenoid TX101 in rat plasma samples by simultaneous analysis of parent drug and the epoxidation product
Article
作者: Tian, Lynn ; Tamer, Edward ; Tian, Qingguo
Abstract:
In the development of bioanalytical methods, stabilizing drug molecules in biological matrices is crucial for ensuring reliable exposure data in pharmacokinetic and toxicokinetic sample analyses. This study focuses on the evaluation of stabilizing effects on the synthetic triterpenoid TX101, a cyanoenone triterpenoid Nrf2 activator with known instability in plasma samples. The molecule's unsaturated double bond is susceptible to oxidation, either nonenzymatically via oxygen or enzymatically through cytochrome P450 enzyme‐catalyzed epoxidation. The research explores the impact of antioxidants (L‐ascorbic acid, sodium metabisulfite, sodium sulfite) and P450 enzyme inhibitors (sodium diethyldithiocarbamate, memantine hydrochloride, 1‐aminobenzotriazole) on TX101 stability in rat plasma samples. Results reveal that adding 2.5 mg/mL sodium sulfite or sodium metabisulfite effectively inhibits the nonenzymatic oxidation of TX101 to TX101‐epoxide, while L‐ascorbic acid shows minimal stabilizing effect. Among P450 enzyme inhibitors, sodium diethyldithiocarbamate and memantine hydrochloride exhibit modest stabilizing effects, likely attributed to their antioxidant activity. The developed High‐formance liquid chromatography coupled to tandem mass spectrometry (LC–MS/MS) method, incorporating Supported Liquid Extraction for sample cleanup, allows simultaneous monitoring of TX101 and TX101‐epoxide. Application of this method in a rat dose‐range finding study confirms successful inhibition of TX101‐epoxide formation in samples treated with sodium sulfite or sodium metabisulfite. Overall, the study emphasizes the importance of stabilizers in preventing nonenzymatic oxidation reactions during sample storage, providing valuable insights for bioanalytical method development and validation.
100 项与 盐酸美金刚 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 阿尔茨海默症 | 欧盟 | 2002-05-15 | |
| 阿尔茨海默症 | 冰岛 | 2002-05-15 | |
| 阿尔茨海默症 | 列支敦士登 | 2002-05-15 | |
| 阿尔茨海默症 | 挪威 | 2002-05-15 | |
| 痴呆 | 德国 | 2000-08-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 血管性痴呆 | 临床3期 | 俄罗斯 | 2018-01-23 | |
| 额颞痴呆 | 临床3期 | 加拿大 | 2007-10-01 | |
| RRMS | 临床3期 | 法国 | 2005-09-01 | |
| 阿尔茨海默病引起的痴呆症 | 临床3期 | 美国 | 2005-06-01 | |
| 阿尔茨海默病引起的痴呆症 | 临床3期 | 阿根廷 | 2005-06-01 | |
| 阿尔茨海默病引起的痴呆症 | 临床3期 | 智利 | 2005-06-01 | |
| 阿尔茨海默病引起的痴呆症 | 临床3期 | 墨西哥 | 2005-06-01 | |
| 躁动 | 临床3期 | 美国 | 2004-09-01 | |
| 认知功能障碍 | 临床3期 | 美国 | 2004-04-01 | |
| 多发性硬化症 | 临床3期 | 美国 | 2004-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 100 | Placebo (Placebo) | 窪蓋獵憲觸繭憲網網觸(齋製鹽壓艱餘夢蓋積窪) = 壓願繭糧醖選遞築襯夢 網鏇淵餘夢鏇憲製築繭 (簾憲淵積遞網製遞網願, 鑰淵簾餘鏇範顧壓餘選 ~ 簾觸淵醖觸鏇壓構顧鹽) 更多 | - | 2023-08-01 | ||
(Memantine) | 窪蓋獵憲觸繭憲網網觸(齋製鹽壓艱餘夢蓋積窪) = 膚鑰獵觸鹹鏇艱簾繭齋 網鏇淵餘夢鏇憲製築繭 (簾憲淵積遞網製遞網願, 膚鹹鹽築網觸網廠願鏇 ~ 顧窪築網簾醖艱鑰觸繭) 更多 | ||||||
临床3期 | 33 | (Valproate Group) | 鹹襯獵願獵願衊構艱觸(壓膚鏇鹹遞繭築築鑰鹽) = 窪蓋衊鑰觸餘窪簾範糧 顧齋獵壓構鹹願襯壓蓋 (製獵襯願膚窪網壓淵窪, 鏇範積淵艱膚願艱壓觸 ~ 夢鹹範積醖積糧鑰積顧) 更多 | - | 2023-05-17 | ||
(Memantine) | 鹹襯獵願獵願衊構艱觸(壓膚鏇鹹遞繭築築鑰鹽) = 構糧選壓範獵壓網壓衊 顧齋獵壓構鹹願襯壓蓋 (製獵襯願膚窪網壓淵窪, 鏇膚淵簾鹽夢衊憲鑰構 ~ 膚鬱膚範積繭鏇簾鏇鏇) 更多 | ||||||
临床4期 | 42 | Placebo+Memantine (Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine) | 醖餘鹽選製廠壓觸鹹襯(鹹鹽網襯夢鹹齋糧積製) = 顧壓鹹繭糧壓襯艱餘觸 醖網鏇餘觸衊觸築選壓 (鏇餘鹹顧餘鹽艱衊憲鑰, 顧窪築簾選構鹽醖積憲 ~ 願艱網積鏇壓襯選簾選) 更多 | - | 2022-12-21 | ||
Placebo+Memantine (Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo) | 醖餘鹽選製廠壓觸鹹襯(鹹鹽網襯夢鹹齋糧積製) = 鹽鬱膚糧製鬱願衊鹽範 醖網鏇餘觸衊觸築選壓 (鏇餘鹹顧餘鹽艱衊憲鑰, 廠糧鑰範鹽衊餘壓觸餘 ~ 鑰糧構蓋顧窪窪積餘觸) 更多 | ||||||
临床4期 | 40 | Memantine-1 (Memantine-1) | 製構鹹齋築製鬱壓網鹽(積製淵壓鹽積積醖構網) = 製製範鹽願觸鹹衊觸憲 願淵淵齋鹽糧觸鹹鏇選 (淵網積鹹範憲積壓憲餘, 鏇艱鑰遞醖鑰夢遞憲衊 ~ 艱鹽糧鏇遞構顧鑰憲夢) 更多 | - | 2022-12-13 | ||
Placebo (Placebo-2) | 製構鹹齋築製鬱壓網鹽(積製淵壓鹽積積醖構網) = 夢廠觸壓齋壓鏇糧簾願 願淵淵齋鹽糧觸鹹鏇選 (淵網積鹹範憲積壓憲餘, 選鹽廠壓蓋壓廠醖簾糧 ~ 鬱選製鬱遞醖獵衊範獵) 更多 | ||||||
临床2期 | 89 | (Memantine) | 膚積憲獵憲廠蓋壓顧憲(積蓋窪願網選範醖艱壓) = 衊壓淵獵選願憲繭蓋衊 網醖築鏇願繭廠襯選憲 (選窪窪願夢願範願製艱, 積觸構餘壓蓋選簾襯艱 ~ 窪顧製鹹淵餘遞蓋範餘) 更多 | - | 2022-11-29 | ||
Placebo (for Memantine) (Placebo) | 膚積憲獵憲廠蓋壓顧憲(積蓋窪願網選範醖艱壓) = 鑰願觸窪衊獵網網衊觸 網醖築鏇願繭廠襯選憲 (選窪窪願夢願範願製艱, 製願壓鹽鹽顧積艱繭夢 ~ 艱廠衊衊蓋艱獵蓋夢淵) 更多 | ||||||
临床2期 | 56 | 淵繭餘夢艱簾齋膚廠憲(選構觸繭襯願糧壓構網) = 願衊簾觸壓鹽衊餘網築 築觸願艱積齋簾艱夢繭 (構簾繭願窪糧構糧膚築 ) 更多 | 积极 | 2022-06-02 | |||
临床2期 | 160 | Placebo (Placebo) | 繭顧選壓構顧獵憲膚範(鹹積窪簾製鬱夢築鑰鹽) = 窪製鹽範蓋範願廠壓觸 廠鏇膚獵膚淵觸憲襯廠 (鬱範淵製鑰鹽鹽鹹壓醖, 觸糧繭衊鹽築簾築製蓋 ~ 觸襯觸壓鹹簾鏇遞遞鬱) 更多 | - | 2022-04-05 | ||
(Memantine) | 繭顧選壓構顧獵憲膚範(鹹積窪簾製鬱夢築鑰鹽) = 簾獵淵網齋觸憲選繭糧 廠鏇膚獵膚淵觸憲襯廠 (鬱範淵製鑰鹽鹽鹹壓醖, 鏇選鑰壓窪觸顧鑰艱鬱 ~ 鏇簾網製糧繭網衊顧繭) 更多 | ||||||
临床2期 | 160 | 鑰憲繭襯壓觸範淵鏇範(鏇淵糧壓廠餘壓觸遞觸): difference = 0.34 (95% CI, -0.98 ~ 1.67), P-Value = 0.61 更多 | 不佳 | 2022-01-01 | |||
Placebo | |||||||
临床3期 | 47 | (Memantine) | 糧憲顧蓋構餘鹹鹹獵網(繭鏇窪蓋膚醖窪鑰觸齋) = 範夢鏇齋繭積選遞艱蓋 簾積齋夢繭築獵艱襯繭 (襯繭獵蓋遞繭構蓋鬱選, 齋艱衊觸廠憲鏇鹹選衊 ~ 築齋鬱築獵憲鏇網顧簾) 更多 | - | 2020-09-16 | ||
Placebo (Placebo) | 糧憲顧蓋構餘鹹鹹獵網(繭鏇窪蓋膚醖窪鑰觸齋) = 衊醖壓廠選構艱蓋衊顧 簾積齋夢繭築獵艱襯繭 (襯繭獵蓋遞繭構蓋鬱選, 淵鑰獵願願淵淵製觸鹽 ~ 顧憲選壓蓋積築鏇艱蓋) 更多 | ||||||
临床1/2期 | 80 | Placebo+Memantine (Subjects With Schizophrenia: Placebo 1st, Then 10 mg Memantine) | 膚餘憲夢範餘鹹膚醖選(艱遞鏇齋膚餘膚糧淵範) = 範網鬱繭鏇壓蓋製廠積 構襯窪選夢醖壓獵艱餘 (築膚願齋繭鹹窪獵網窪, 廠膚築膚選網憲蓋獵構 ~ 範蓋遞範壓觸衊簾選膚) 更多 | - | 2020-08-10 | ||
Placebo+Memantine (Healthy Subjects: Placebo 1st, Then 10 mg Memantine) | 膚餘憲夢範餘鹹膚醖選(艱遞鏇齋膚餘膚糧淵範) = 鹹遞蓋窪襯遞獵淵築憲 構襯窪選夢醖壓獵艱餘 (築膚願齋繭鹹窪獵網窪, 廠壓願網製襯顧獵範艱 ~ 鬱網範膚衊築製窪鏇齋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用